ABSTRACT
This chapter considers the precautionary principle (PP) in relation to a pressing issue in current health research known as sponsorship bias. Sponsorship bias refers to the tendency of industry-funded clinical trials to reach conclusions that align with the financial interests of their sponsors. Critics charge that commonly adopted measures, such as conflict of interest disclosure requirements, are inadequate and call for more forceful solutions to sponsorship bias. Three such proposals are adversarial proceedings, sequestration, and restriction/elimination of intellectual property rights for biomedical innovations. I evaluate these three proposals from the perspective of PP.
